MA48798A - Procédé de production d'ozanimod - Google Patents

Procédé de production d'ozanimod

Info

Publication number
MA48798A
MA48798A MA048798A MA48798A MA48798A MA 48798 A MA48798 A MA 48798A MA 048798 A MA048798 A MA 048798A MA 48798 A MA48798 A MA 48798A MA 48798 A MA48798 A MA 48798A
Authority
MA
Morocco
Prior art keywords
ozanimod
production process
production
ozanimod production
Prior art date
Application number
MA048798A
Other languages
English (en)
Other versions
MA48798B1 (fr
Inventor
Judit Halász
Eniko Molnár
János Petho
Márta Porcs-Makkay
Gyula Simig
Éva Szabó
László Szlávik
Balázs Volk
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of MA48798A publication Critical patent/MA48798A/fr
Publication of MA48798B1 publication Critical patent/MA48798B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA48798A 2017-05-22 2018-05-18 Procédé de production d'ozanimod MA48798B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1700216 2017-05-22
PCT/HU2018/050019 WO2018215807A1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Publications (2)

Publication Number Publication Date
MA48798A true MA48798A (fr) 2020-04-08
MA48798B1 MA48798B1 (fr) 2023-10-31

Family

ID=89720175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48798A MA48798B1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Country Status (12)

Country Link
US (1) US12459907B2 (fr)
EP (1) EP3630738B1 (fr)
CN (1) CN110997645B (fr)
EA (1) EA201992421A1 (fr)
ES (1) ES2960051T3 (fr)
HR (1) HRP20231308T1 (fr)
HU (1) HUE064642T2 (fr)
MA (1) MA48798B1 (fr)
PL (1) PL3630738T3 (fr)
PT (1) PT3630738T (fr)
SI (1) SI3630738T1 (fr)
WO (1) WO2018215807A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094409A1 (fr) * 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Sels et formes à l'état solide d'ozanimod
WO2020115200A1 (fr) * 2018-12-07 2020-06-11 Synthon B.V. Procédé amélioré pour la préparation d'ozanimod
WO2020152718A1 (fr) * 2019-01-25 2020-07-30 Mylan Laboratories Limited Formes polymorphes de 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyéthyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-méthyléthoxy)benzonitrile
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US12404256B2 (en) 2019-07-16 2025-09-02 Synthon B.V. Process for preparing ozanimod
WO2021084068A1 (fr) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1
EP4126826A1 (fr) 2020-04-02 2023-02-08 Synthon B.V. Forme cristalline d'hydrochlorure d'ozanimod
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500676A1 (en) 2009-10-08 2015-06-03 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
RS61829B1 (sr) 2009-11-13 2021-06-30 Receptos Llc Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
WO2015066515A1 (fr) * 2013-11-01 2015-05-07 Receptos, Inc. Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
ES3022204T3 (en) * 2016-06-14 2025-05-28 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
WO2018033149A1 (fr) 2016-08-19 2018-02-22 苏州科睿思制药有限公司 Forme cristalline d'ozanimod et leur procédé de préparation
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
EP3518922B1 (fr) * 2016-09-29 2026-02-11 Receptos LLC Composés et méthodes de traitement du lupus

Also Published As

Publication number Publication date
PT3630738T (pt) 2023-10-24
MA48798B1 (fr) 2023-10-31
EA201992421A1 (ru) 2020-03-27
HRP20231308T1 (hr) 2024-04-26
EP3630738B1 (fr) 2023-07-19
US20200087269A1 (en) 2020-03-19
CN110997645B (zh) 2023-10-10
SI3630738T1 (sl) 2024-02-29
ES2960051T3 (es) 2024-02-29
US12459907B2 (en) 2025-11-04
WO2018215807A1 (fr) 2018-11-29
PL3630738T3 (pl) 2024-04-08
EP3630738A4 (fr) 2021-03-10
HUE064642T2 (hu) 2024-04-28
EP3630738A1 (fr) 2020-04-08
CN110997645A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
EP3378869A4 (fr) Procédé de production d'oligonucléotide
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3702346A4 (fr) Procédé de production d'hexafluorobutadiène
MA48723A (fr) Procédé de production d'anticorps multispécifiques
MA48798A (fr) Procédé de production d'ozanimod
EP3613404A4 (fr) Procédé de production de film
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3354677A4 (fr) Procédé de production d'un copolymère de polycarbonate-polyorganosiloxane
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3747624A4 (fr) Procédé de production de structure
EP3388390A4 (fr) Procédé de production d'ozone
EP3327066A4 (fr) Procédé de production d'article coagulé
EP3734620A4 (fr) Procédé de production d'électrode transparente
EP3633713A4 (fr) Procédé de production d'une structure et structure
EP3594250A4 (fr) Procédé de production de polymère
EP3447042A4 (fr) Procédé de production de 1,2-dichlorohexafluorocyclopentène
EP3684757A4 (fr) Procédé de production d'alkylaromatiques
EP3704551A4 (fr) Procédé de production distribuée
EP3778560A4 (fr) Procédé de production d'acrylonitrile
EP3831804A4 (fr) Procédé de production de 1-acyloxy-2-méthyl-2-propène
EP3348331A4 (fr) Procédé de production d'un article revêtu
EP3705473A4 (fr) Procédé de production de dihydroxyindoles
EP3689852A4 (fr) Procédé de production de dihydroxyindoles
EP3659800A4 (fr) Procédé de production d'un stratifié
EP3640216A4 (fr) Procédé d'adsorption